Summary of Phathom Pharmaceuticals FY Conference Call Company Overview - **Company**: Phathom Pharmaceuticals (NasdaqGS:PHAT) - **Product**: VOQUEZNA, a first-in-class potassium-competitive acid blocker for treating gastroesophageal reflux disease (GERD) [2][3] Financial Performance - **2025 Revenue**: $175.1 million, up from $55 million in 2024 [3][4] - **2026 Revenue Guidance**: Expected to be between $320 million and $345 million, indicating a growth of over $140 million from 2025 [4][25] - **Operating Profitability**: Expected in the second half of 2026, with positive free cash flow anticipated from 2027 [4][27] - **Cash Usage**: Significant reduction in cash usage from $85 million in Q1 2025 to $5 million in the last quarter [24] Market Opportunity - **Target Market**: 22 million patients treated with prescription PPIs annually, with 40% still experiencing symptoms [5][6] - **Potential Revenue**: Estimated $1 billion opportunity in GI practices and another $1 billion in primary care [7][17] - **Prescription Growth**: 273,000 scripts last quarter, with a target of 4-6 million prescriptions per year to reach $1 billion in revenue [14][15] Product Advantages - **Mechanism of Action**: VOQUEZNA offers rapid, potent, and durable pH elevation, providing better relief for patients inadequately treated by PPIs [8][9] - **Patient Journey**: Focus on patients who have failed PPI therapy and are experiencing significant pain, leading to referrals to gastroenterologists [10][11] Sales Strategy - **Sales Organization Realignment**: Shifted focus to GI practices, with 70% of sales calls now targeting GI specialists [12][13] - **Top Prescribers**: The top 300 GI writers have converted about 20% of their prescriptions to VOQUEZNA, with plans to expand this rate across the GI community [18] Regulatory and Competitive Landscape - **IP and Exclusivity**: VOQUEZNA has a 10-year exclusivity under the GAIN Act, preventing generic entry until May 2032 [29][30] - **Market Assessment for OTC**: Exploring potential for over-the-counter sales post-2033, but currently focused on prescription market [36] Patient Retention and Feedback - **Prescription Persistence**: Majority of patients fill multiple prescriptions, with an average of 6-7 refills in the first year [33] - **Feedback Loop**: Importance of physician feedback from patients to drive adoption and confidence in prescribing VOQUEZNA [38][39] Conclusion - **Growth Trajectory**: Phathom Pharmaceuticals is on a solid growth trajectory with a clear path to profitability, focusing on the GI market and leveraging the unique advantages of VOQUEZNA to capture significant market share [28]

Financial Data and Key Metrics Changes - For the full year 2025, net revenues were $175.1 million, representing a 217% year-over-year growth, with Q4 revenue at $57.6 million, consistent with pre-release estimates [8][16] - Cash operating expenses for Q4 were $50.3 million, better than the guidance of less than $55 million, and full-year cash operating expenses were approximately $284 million, at the low end of the range provided [9][18] - The company reported a loss from operations of approximately $320,000 for Q4, a 95% improvement compared to Q3 [17] Business Line Data and Key Metrics Changes - The sales organization is positioned to deliver growth, with over 1.1 million total prescriptions of VOQUEZNA filled to more than 230,000 patients, indicating strong market penetration [12] - In Q4, 273,000 prescriptions were filled, with 174,000 being covered prescriptions, representing a 21% quarter-over-quarter growth [12] Market Data and Key Metrics Changes - The company targets a market of approximately 65 million patients with gastroesophageal reflux, of which 40% experience inadequate symptom relief from PPIs [12] - The gross margin remained consistent at approximately 87% for both Q4 and the full year [17] Company Strategy and Development Direction - The company aims to achieve operating profitability beginning in Q3 2026 and cash flow positivity in 2027, with a revenue guidance of $320 million-$345 million for 2026 [7][24] - The focus is on enhancing the capital structure, reducing interest expenses, and executing a GI-focused strategy to drive growth [6][10] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth trajectory for 2026, citing strong momentum and a nearly full-strength sales organization [14][15] - The company is not anticipating a fundamental change in broad Medicare coverage but is seeing incremental increases in Medicare prescriptions being covered [52] Other Important Information - The company successfully modified its term loan agreement, extending the maturity date to February 2029 and reducing the interest rate from 12% to 9.85% [19] - The company is exploring potential partnerships and additional products to expand its GI pipeline, although currently focusing on VOQUEZNA and its existing strategy [81][83] Q&A Session Summary Question: Early signals from the strengthened sales force and strategy - Management noted consistent signs of momentum, with a high percentage of gastroenterologists already writing prescriptions for VOQUEZNA and efforts focused on increasing writing frequency [31][32] Question: Dynamics of patients transitioning back to primary care - Management acknowledged an uplift in primary care prescribing volume but emphasized the current focus on gastroenterology [39] Question: Q1 sequential growth expectations - Management indicated typical seasonality effects and acknowledged that Q1 is generally the slowest quarter, but underlying metrics provide confidence for the full year [46][50] Question: Proportions of prescriptions filled through BlinkRx and GoodRx - Management reported that over half of prescriptions are routed through BlinkRx, with a small percentage utilizing GoodRx since its launch in November [60][65] Question: Long-term vision beyond VOQUEZNA - Management is actively considering additional products for the GI pipeline but is currently focused on executing the strategy for VOQUEZNA [80][83]

NASDAQ: PHAT Today's Agenda Business Update FOURTH QUARTER & FULL YEAR 2025 EARNINGS CONFERENCE CALL FEBRUARY 2026 Steven Basta, President & Chief Executive Officer Financial Update Sanjeev Narula, Chief Financial and Business Officer Closing Remarks Steven Basta, President & Chief Executive Officer Question & Answer Steven Basta, President & Chief Executive Officer Sanjeev Narula, Chief Financial and Business Officer 2 Safe harbor This presentation contains forward-looking statements. All statements other ...

Core Insights - Phathom Pharmaceuticals reported significant revenue growth in 2025, with a net revenue of $175.1 million, a 217% increase from 2024 [12][20] - The company anticipates operating profitability beginning in Q3 2026 and aims to achieve cash flow positivity by 2027 [2][13] Financial Performance - Q4 2025 net revenues were $57.6 million, up from $29.7 million in Q4 2024, reflecting a $27.9 million increase [12] - Full year 2025 operating expenses were $312.5 million, a decrease from $324.7 million in 2024, with non-GAAP operating expenses at $283.8 million [11] - The net loss for Q4 2025 was $21.1 million, significantly reduced from $74.5 million in Q4 2024 [12] Business Developments - Phathom's sales force was realigned in Q4 2025, achieving over 95% strength, and new marketing leadership was recruited to enhance engagement with gastroenterologists [7] - More than 1.1 million VOQUEZNA prescriptions have been filled as of February 2026, with a 24% increase in Q4 prescriptions compared to the previous quarter [7] Capital Structure - The company completed a $130 million equity offering in January 2026, enhancing its financial position [8] - A modification of the term debt facility reduced overall debt and extended the maturity date to February 2029, with a remaining principal of $175 million [9] 2026 Financial Guidance - Phathom expects net revenues of $320–$345 million for 2026, with a gross margin of approximately 80% and non-GAAP operating expenses of $235–$250 million [20] - The company will include certain third-party charges in cost of goods sold starting January 1, 2026, affecting revenue classification [15]

Core Insights - The company is shifting its sales focus towards gastroenterologists, who are seen as early adopters for treating patients with gastroesophageal reflux disease (GERD) [1][5] - Phathom Pharmaceuticals expects to achieve operating profitability in the second half of 2026 [2] - The company generated $55 million in revenue in 2024 and anticipates $175 million for 2025 [3] Business Strategy - The strategic pivot towards gastroenterology aims to target patients who remain symptomatic despite existing therapies, with approximately 40% of reflux patients still experiencing pain [4][5] - The company plans to maintain tighter operating expense discipline while continuing revenue growth through this focused approach [5][6] - Phathom is refilling open territories and aims to have around 300 sales representatives by the end of March [6] Market Dynamics - A seasonal dip in January prescriptions is attributed to typical market dynamics, including insurance plan resets and prior authorization requirements [8] - The company believes it can convert 20% to 30% of gastroenterology PPI script volume to its product VOQUEZNA, potentially generating $1 billion in revenue from this segment [12][13] Pipeline and Development - Phathom is developing an eosinophilic esophagitis (EoE) program, which could provide significant economic benefits and potential exclusivity extensions [14][15] - The company is exploring longer-term business development opportunities that align with its gastroenterology focus [17] Financial Position - A recent capital raise was aimed at addressing a significant debt overhang and improving the company's capital structure [10] - The company has a new chemical entity (NCE) exclusivity that extends through May 2032, with potential for further extensions [16]

Summary of Phathom Pharmaceuticals Conference Call Company Overview - **Company**: Phathom Pharmaceuticals (NasdaqGS:PHAT) - **Product**: VOQUEZNA, the first PCAB (Potassium-Competitive Acid Blocker) in the U.S. for gastroesophageal reflux disease (GERD) treatment - **Market Size**: 65 million patients in the U.S. suffer from gastroesophageal reflux, with a historical PPI market exceeding $10 billion in revenue [2][3][9] Core Insights - **Market Opportunity**: 40% of GERD patients on standard therapy (PPIs) are still in pain, representing a significant opportunity for VOQUEZNA to convert these patients to a more effective treatment [3][4] - **Sales Growth**: - 2024 revenue: $55 million - 2025 revenue: Estimated $175 million, indicating a growth of $120 million year-over-year [9] - Expected transition to operating profitability in the second half of 2026 [10] - **Sales Strategy Shift**: Focus has shifted from primary care to gastroenterologists, who are identified as early adopters and the primary prescribers for patients in pain [10][11][14] Financial Performance - **Revenue Growth**: Consistent growth observed each quarter in 2025 despite sales force transitions and territory realignments [27][31] - **Sales Force Realignment**: - Target lists were updated to focus on gastroenterologists, removing unproductive primary care targets [20][22] - Full-strength sales organization expected by March 2026, with approximately 300 sales reps [22] Market Penetration Goals - **PPI Market Penetration**: Current penetration at 3% of the PPI script volume within gastroenterology, with a goal to convert 20%-30% of the 20 million PPI prescriptions written by gastroenterologists, potentially leading to $1 billion in revenue [78][84] Future Outlook - **2026 Strategy**: Focus on executing the current strategy without major shifts, emphasizing sales execution and customer engagement [41][42] - **EoE Market Potential**: Ongoing trials for eosinophilic esophagitis (EoE) could extend exclusivity and provide additional revenue opportunities [96][108] - **Pipeline Development**: Plans to explore additional products for launch through existing gastroenterology relationships, focusing on assets with clear human efficacy data [123][126] Additional Considerations - **Debt Management**: Recent capital raise aimed at improving the balance sheet and renegotiating debt terms to alleviate investor concerns [73] - **Seasonal Fluctuations**: January script declines attributed to seasonal factors and insurance plan resets, not indicative of underlying demand [46][50] This summary encapsulates the key points discussed during the conference call, highlighting Phathom Pharmaceuticals' strategic focus, financial performance, and future growth opportunities in the gastroenterology market.

Company Overview - Phathom Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases [3] - The company has in-licensed exclusive rights to vonoprazan, a first-in-class potassium-competitive acid blocker (PCAB), for the U.S., Europe, and Canada [3] - Phathom markets vonoprazan in the U.S. as VOQUEZNA® for various gastrointestinal conditions, including heartburn associated with Non-Erosive GERD and H. pylori infection treatment [3] Upcoming Events - Members of Phathom's management team will participate in a fireside chat at the Guggenheim Emerging Outlook Biotech Summit 2026 on February 12, 2026 [1] - The conference will take place from February 11-12, 2026, in New York, NY, and will include one-on-one meetings [2] - A live webcast and archived recordings of the event will be available on Phathom's website for 90 days following the meeting [2]

Core Insights - Phathom Pharmaceuticals, Inc. reported preliminary unaudited financial results for Q4 and full year 2025, indicating significant revenue growth and operational milestones [1][6]. Group 1: Preliminary Financial Results - For Q4 2025, Phathom expects net revenues of approximately $57 million to $58 million, with GAAP operating expenses of approximately $59 million to $61 million and non-GAAP operating expenses of approximately $51 million to $53 million, excluding about $8 million of stock-based compensation [8]. - For the full year 2025, net revenues are anticipated to be around $174.5 million to $175.5 million, with GAAP operating expenses of approximately $315.5 million to $317.5 million and non-GAAP operating expenses of approximately $284.5 million to $286.5 million, excluding about $31 million of stock-based compensation [8]. Group 2: Product Milestones - Phathom surpassed one million prescriptions dispensed for VOQUEZNA products in the U.S. since its launch during Q4 2025 [4]. Group 3: Future Outlook - The company anticipates achieving operating profitability in the second half of 2026, excluding stock-based compensation [5].

Summary of Phathom Pharmaceuticals Conference Call Company Overview - **Company**: Phathom Pharmaceuticals - **Product**: VOQUEZNA, a next-generation treatment for gastroesophageal reflux disease (GERD) licensed from Takeda, which has shown significant success in Japan [2][4] Market Opportunity - **Target Market**: Focus on the 30%-40% of GERD patients who are on PPIs (Proton Pump Inhibitors) but still experience symptoms [3][6] - **Revenue Growth**: Achieved $55 million in revenue in 2024, with guidance for $170-$175 million in 2025 [3] - **Gastroenterology Focus**: Shifted strategy to concentrate on gastroenterology, which is expected to drive growth over the next few years [3][19] Competitive Landscape - **Market Positioning**: VOQUEZNA is not positioned as a direct competitor to PPIs; it is intended for patients who have failed prior PPI therapy [12][13] - **Prescription Opportunity**: There are approximately 20 million PPI prescriptions written annually by gastroenterologists, representing a significant market for VOQUEZNA [7][9] Sales Strategy - **Sales Force Reallocation**: 70% of sales efforts are now focused on gastroenterologists, up from 30% previously targeting primary care [19][21] - **Productivity Metrics**: Sales calls to gastroenterologists yield four times the productivity compared to primary care [21] Exclusivity and Regulatory Strategy - **Exclusivity Timeline**: VOQUEZNA has exclusivity through May 2032, with potential extensions into 2034 depending on ongoing trials and FDA reviews [28][29] - **GAINS Act Utilization**: The company successfully leveraged the GAINS Act to extend exclusivity for the product [27] Financial Projections - **Revenue Potential**: Aiming for $1 billion in revenue from the gastroenterology market, with a clear path to achieving this through increased market penetration [10][36] - **Growth Rate Stability**: The company has maintained a stable growth rate despite the transition in sales strategy [24][44] Coverage and Access - **Insurance Coverage**: VOQUEZNA is covered by over 80% of commercial lives, with varying requirements for prior PPI failures [17][46] - **Cash Pay Strategy**: The company is also focusing on cash pay prescriptions to ensure patient access, which can later convert to covered prescriptions [53][56] Patient Experience and Persistence - **Patient Retention**: Early data suggests strong persistence rates for patients switching to VOQUEZNA, driven by significant symptom relief [42][40] - **Long-term Outlook**: The company anticipates that positive patient experiences will lead to sustained prescription growth over time [57] Conclusion - Phathom Pharmaceuticals is strategically positioned to capture a significant share of the GERD treatment market through VOQUEZNA, with a focused sales strategy, strong revenue growth, and a clear path to exclusivity that supports long-term financial success [36][58]

Summary of Phathom Pharmaceuticals Conference Call Company Overview - **Company**: Phathom Pharmaceuticals - **Product**: VOQUEZNA, a first-in-class P-CAB approved for gastroesophageal reflux disease (GERD) treatment - **Market Focus**: Targeting patients who are refractory to traditional PPI therapies Key Points and Arguments Commercial Strategy and Market Focus - Phathom has pivoted its commercial strategy to focus more on the gastroenterology (GI) community, which is where the majority of patients experiencing significant GERD symptoms are referred [4][6] - The company aims to target the 20 million PPI prescriptions written within GI practices, with a current penetration of approximately 3% [10][11] - The goal is to increase penetration to 20%-30% within the GI community, potentially generating $1 billion in revenue from this segment alone [12] Financial Performance - Revenue growth has been significant, with $10 million increases from Q1 to Q2 and Q2 to Q3, reaching $49.5 million in Q3 [7][8] - Operating expenses were reduced from $98 million in Q1 to $49 million in Q3, achieving a 50% cut in cash operating expenses [8] - The company expects to reach positive operating profit by 2026, focusing on cash basis excluding stock compensation and interest expenses [9] Sales Force Realignment - The sales force has been realigned to focus 70% of their time on gastroenterologists, shifting from a previous 70/30 split favoring primary care [20][27] - Territories have been remapped to optimize call frequency on gastroenterologists, allowing for better engagement and education about VOQUEZNA [29] Adoption and Utilization - Adoption patterns among physicians are gradual, with initial focus on patients who have failed multiple PPI therapies [18][19] - The company tracks physician prescribing frequency to reinforce habits and increase script volume [45][46] - There is a strong emphasis on patient feedback to encourage physician adoption, as patients report significant improvements in their symptoms [32][66] Medicare and Patient Access - The introduction of Medicare coverage has positively impacted prescription volumes, with a notable increase in cash prescriptions due to the availability of the Blink patient assistance platform [48][56] - The company is tracking both covered and cash prescriptions separately, with cash prescriptions growing since the Medicare rollout [49][56] Future Opportunities - Phathom is initiating a clinical trial for eosinophilic esophagitis (EOE), which could lead to additional market opportunities and an extension of exclusivity for VOQUEZNA [67][70] - Successful trials could result in a six-month exclusivity extension, potentially delaying generic competition until late 2033 or 2034 [70] Additional Important Insights - The company has implemented financial discipline in its spending, which is expected to support future profitability [72] - The transformative effect of VOQUEZNA on patient quality of life is a key selling point that is expected to drive further adoption among physicians [33][66]